(-0.21%) 5 000.82 points
(0.49%) 37 961 points
(-0.91%) 15 459 points
(0.31%) $82.99
(2.22%) $1.796
(0.28%) $2 404.80
(0.69%) $28.58
(-1.17%) $943.30
(-0.29%) $0.937
(-0.50%) $10.99
(-0.19%) $0.802
(-0.81%) $93.14
Live Chart Being Loaded With Signals
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy...
Stats | |
---|---|
Today's Volume | 34 959.00 |
Average Volume | 56 130.00 |
Market Cap | 76.23M |
EPS | SEK-0.424 ( 2023-09-30 ) |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.850 |
ATR14 | SEK0.0540 (1.40%) |
CombiGene AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CombiGene AB (publ) Financials
Annual | 2023 |
Revenue: | SEK5.54M |
Gross Profit: | SEK-38.78M (-699.55 %) |
EPS: | SEK-1.800 |
Q4 | 2023 |
Revenue: | SEK596 000 |
Gross Profit: | SEK-8.89M (-1 492.11 %) |
EPS: | SEK-0.320 |
Q3 | 2023 |
Revenue: | SEK1.17M |
Gross Profit: | SEK-8.27M (-710.13 %) |
EPS: | SEK-0.420 |
Q2 | 2023 |
Revenue: | SEK1.79M |
Gross Profit: | SEK-7.70M (-430.59 %) |
EPS: | SEK-0.320 |
Financial Reports:
No articles found.
CombiGene AB (publ)
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators